# Century Therapeutics, Inc. (IPSC) · Edgar & Edgarette company card

> Century Therapeutics, Inc. (IPSC) grew revenue 1557% in FY2025 to $109 million, operating margin -15.8%, in line with the -15.8% median for biological products, (no diagnostic substances), equity 71.0% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1850119 · fiscal year ended 2025-12-31 · 4 audited years read · [page](https://www.pops4.com/boards/company/IPSC) · [JSON](https://www.pops4.com/boards/company/IPSC.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $109M |
| Revenue growth, 1 year | 1556.8% |
| Revenue growth per year | 175.8% |
| Operating margin | -15.8% (prior year -2096.5%) |
| Net margin | -8.8% |
| Operating cash flow | −$104M |
| Capital spending | $848,000 |
| Free cash flow | −$105M |
| Cash | $62M |
| Long-term debt | — |
| Total assets | $224M |
| Total equity | $159M |
| Equity ÷ assets | 71.0% |
| Return on equity | -6.0% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -6.53 (distress zone)
- Piotroski F: 4 of 9 (middling)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative; operating loss: a margin of -15.8% in FY2025; revenue is hard to predict: its 80% range is ±81%
- Cash Compass: Fast, cash not yet · growing fast, but little cash arriving so far

## Edgarette's reading

Exposure: revenue $109.2M (FY2025). Experience: revenue up 1556.8% on the year, up 175.8% a year over 3 years; operating margin -15.8%, up from -2096.5%. Soundness: equity 71.0% of assets, return on equity -6.0%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $342.3M and $3.2B next year (method v4.1: its own 2-year record of growth weighed at 25% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $193.8M to $5.9B. A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin -15.8% against a -15.8% median; growth 1556.8% against 21.4%.

Range logged 2026-09-25, receipt 019893adbf76d42f, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 4, latest 2026-09-09 ([filing](https://www.sec.gov/Archives/edgar/data/1850119/000110465926106312/0001104659-26-106312-index.htm))

## Recent filings

- 8-K · filed 2026-10-02 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1850119/000110465926113055/0001104659-26-113055-index.htm)
- 8-K · filed 2026-09-09 · 5.02 Departure or Election of Directors; Appointment of Officers; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1850119/000110465926106312/0001104659-26-106312-index.htm)
- 8-K · filed 2026-08-12 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1850119/000110465926094533/0001104659-26-094533-index.htm)
- 10-Q · filed 2026-08-12 · [filing](https://www.sec.gov/Archives/edgar/data/1850119/000110465926094523/0001104659-26-094523-index.htm)
- 8-K · filed 2026-06-16 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/1850119/000110465926074577/0001104659-26-074577-index.htm)
- 8-K · filed 2026-06-12 · 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1850119/000110465926073429/0001104659-26-073429-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001850119.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1850119

## Cite

POPS4, Edgar & Edgarette: Century Therapeutics, Inc. (IPSC) company card, from the company's own SEC filings, accessed 2026-11-05, https://www.pops4.com/boards/company/IPSC. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.